The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Oct 8

PMID 34621270

Citations 17

Authors

Lu Meng

Jianfang Xu

Ying Ye

Yingying Wang

Shilan Luo

Xiaomei Gong

Affiliations

Soon will be listed here.

Abstract

Radiotherapy is an effective local treatment modality of NSCLC. Its capabilities of eliminating tumor cells by inducing double strand DNA (dsDNA) damage and modulating anti-tumor immune response in irradiated and nonirradiated sites have been elucidated. The novel ICIs therapy has brought hope to patients resistant to traditional treatment methods, including radiotherapy. The integration of radiotherapy with immunotherapy has shown improved efficacy to control tumor progression and prolong survival in NSCLC. In this context, biomarkers that help choose the most effective treatment modality for individuals and avoid unnecessary toxicities caused by ineffective treatment are urgently needed. This article summarized the effects of radiation in the tumor immune microenvironment and the mechanisms involved. Outcomes of multiple clinical trials investigating immuno-radiotherapy were also discussed here. Furthermore, we outlined the emerging biomarkers for the efficacy of PD-1/PD-L1 blockades and radiation therapy and discussed their predictive value in NSCLC.

Citing Articles

Adverse reactions of immune checkpoint inhibitors combined with angiogenesis inhibitors: A pharmacovigilance analysis of drug-drug interactions.

Ren X, Deng L, Dong X, Bai Y, Li G, Wang Y Int J Immunopathol Pharmacol. 2024; 38:3946320241305390.

PMID: 39660594 PMC: 11632882. DOI: 10.1177/03946320241305390.

Efficacy and Mechanism of Combining Radiotherapy and Immunotherapy in Stage IV Non-Small Cell Lung Cancer.

Wang M, Li S, Li R, Ning F, Tian L Curr Treat Options Oncol. 2024; 25(12):1605-1614.

PMID: 39625619 PMC: 11638397. DOI: 10.1007/s11864-024-01260-x.

miR-1226-5p is involved in radioresistance of colorectal cancer by activating M2 macrophages through suppressing IRF1.

Choi J, Seok H, Lee D, Kwon J, Shin U, Shin I J Transl Med. 2024; 22(1):980.

PMID: 39472937 PMC: 11523791. DOI: 10.1186/s12967-024-05797-1.

Epigenetic modification in radiotherapy and immunotherapy for cancers.

Hung S, Lee M, Chiou W, Liu D, Yu C, Chen L Tzu Chi Med J. 2024; 36(4):396-406.

PMID: 39421493 PMC: 11483092. DOI: 10.4103/tcmj.tcmj_3_24.

Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study.

Volpe S, Zaffaroni M, Piperno G, Vincini M, Zerella M, Mastroleo F BMC Cancer. 2023; 23(1):1236.

PMID: 38102575 PMC: 10722797. DOI: 10.1186/s12885-023-11701-9.

References

Chalmers Z, Connelly C, Fabrizio D, Gay L, Ali S, Ennis R . Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017; 9(1):34. PMC: 5395719. DOI: 10.1186/s13073-017-0424-2. View

Mansfield A, Aubry M, Moser J, Harrington S, Dronca R, Park S . Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol. 2016; 27(10):1953-8. PMC: 5035793. DOI: 10.1093/annonc/mdw289. View

Grimaldi A, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V . Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014; 3:e28780. PMC: 4106166. DOI: 10.4161/onci.28780. View

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

Guibert N, Mazieres J . Nivolumab for treating non-small cell lung cancer. Expert Opin Biol Ther. 2015; 15(12):1789-97. DOI: 10.1517/14712598.2015.1114097. View

Halvorsen A, Sandhu V, Sprauten M, Flote V, Kure E, Brustugun O . Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. Acta Oncol. 2018; 57(9):1225-1231. DOI: 10.1080/0284186X.2018.1465585. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

Kim H, Kim S, Kim S, Park C, Jeung H, Kim Y . Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. BMC Genomics. 2012; 13:348. PMC: 3472294. DOI: 10.1186/1471-2164-13-348. View

Wu S, Liao R, Tu H, Wang W, Dong Z, Huang S . Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. J Thorac Oncol. 2017; 13(4):521-532. DOI: 10.1016/j.jtho.2017.11.132. View

10.

Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I . Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). J Immunother Cancer. 2018; 6(1):63. PMC: 6013904. DOI: 10.1186/s40425-018-0367-1. View

11.

Chowdhary M, Switchenko J, Press R, Jhaveri J, Buchwald Z, Blumenfeld P . Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery. J Neurooncol. 2018; 139(3):689-697. PMC: 6126986. DOI: 10.1007/s11060-018-2914-5. View

12.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

13.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

14.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D . Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(3):351-357. PMC: 5885829. DOI: 10.1001/jamaoncol.2017.4771. View

15.

Li Y, Zhang Z, Hu Y, Yan X, Song Q, Wang G . Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs). Front Oncol. 2020; 10:654. PMC: 7324627. DOI: 10.3389/fonc.2020.00654. View

16.

Ott P, Bang Y, Piha-Paul S, Abdul Razak A, Bennouna J, Soria J . T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol. 2018; 37(4):318-327. DOI: 10.1200/JCO.2018.78.2276. View

17.

Pages F, Mlecnik B, Marliot F, Bindea G, Ou F, Bifulco C . International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391(10135):2128-2139. DOI: 10.1016/S0140-6736(18)30789-X. View

18.

Gong T, Liu L, Jiang W, Zhou R . DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2019; 20(2):95-112. DOI: 10.1038/s41577-019-0215-7. View

19.

Punnanitinont A, Kannisto E, Matsuzaki J, Odunsi K, Yendamuri S, Singh A . Sublethal Radiation Affects Antigen Processing and Presentation Genes to Enhance Immunogenicity of Cancer Cells. Int J Mol Sci. 2020; 21(7). PMC: 7178186. DOI: 10.3390/ijms21072573. View

20.

Ruiz-Banobre J, Areses-Manrique M, Mosquera-Martinez J, Cortegoso A, Afonso-Afonso F, de Dios-Alvarez N . Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. Transl Lung Cancer Res. 2020; 8(6):1078-1085. PMC: 6976357. DOI: 10.21037/tlcr.2019.11.07. View